for the Period Ended 31 May 2024
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 May 2024
Directors
The directors shown below have held office during the whole of the period from
11 May 2023
to
31 May 2024
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
13 months to 31 May 2024 | ||
---|---|---|
|
£ |
|
Turnover: |
|
|
Gross profit(or loss): |
|
|
Administrative expenses: |
(
|
|
Operating profit(or loss): |
|
|
Profit(or loss) before tax: |
|
|
Tax: |
(
|
|
Profit(or loss) for the financial year: |
|
As at
Notes | 13 months to 31 May 2024 | ||
---|---|---|---|
|
£ |
||
Current assets | |||
Cash at bank and in hand: |
|
||
Total current assets: |
|
||
Creditors: amounts falling due within one year: | 3 |
(
|
|
Net current assets (liabilities): |
|
||
Total assets less current liabilities: |
|
||
Accruals and deferred income: |
(
|
||
Total net assets (liabilities): |
|
||
Members' funds | |||
Profit and loss account: |
|
||
Total members' funds: |
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 May 2024
Basis of measurement and preparation
for the Period Ended 31 May 2024
13 months to 31 May 2024 | ||
---|---|---|
Average number of employees during the period |
|
for the Period Ended 31 May 2024
13 months to 31 May 2024 | ||
---|---|---|
£ | ||
Taxation and social security |
|
|
Other creditors |
|
|
Total |
|
We have run a conference and some webinars to discuss best practice for doctors treating infections in patients with implants. This has ensured that doctors and colleagues will still continue to offer the most contemporary treatment to patients with musculoskeletal infections
This years inaugural conference included over 150 of the UKs leading surgeons, nurses and pharmacists. The knowledge exchange and networking was invaluable.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
21 October 2024
And signed on behalf of the board by:
Name: D W Shields
Status: Director